WuXi PharmaTech Files 2009 Annual Report on Form 20-F

SHANGHAI, April 23 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2009 with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to its shareholders and ADS holders upon request. Requests should be directed to Ronald Aldridge, Director of Investor Relations, by email at [email protected] .

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.
     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: [email protected]

     Stephanie Liu (for the media)
     Tel:   +86-21-5046-4362
     Email: [email protected]

SOURCE WuXi PharmaTech (Cayman) Inc.

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.